RXO, Inc. (RXO) director discloses new RSU award and share vesting
Rhea-AI Filing Summary
RXO, Inc. reported an insider equity transaction by one of its directors on 01/02/2026. The director acquired 7,745 shares of common stock at a price of $0 through the conversion of previously granted restricted stock units (transaction code M), bringing direct ownership to 34,275 common shares.
On the same date, the director received a new award of 14,517 restricted stock units (RSUs), each representing the right to receive either one share of common stock or a cash payment equal to its fair market value upon settlement. These RSUs are scheduled to vest in full on January 2, 2027, provided the director continues to serve on the board. Previously granted RSUs vested on January 2, 2026, triggering the share acquisition.
Positive
- None.
Negative
- None.
FAQ
What insider transaction did RXO (RXO) report in this Form 4?
RXO, Inc. reported that a director acquired 7,745 shares of common stock on 01/02/2026 at $0 per share through the vesting and settlement of previously granted restricted stock units.
How many RXO shares does the reporting director own after the transaction?
Following the reported transaction, the director beneficially owns 34,275 shares of RXO common stock in direct ownership.
What new RSU award did the RXO director receive?
On 01/02/2026, the director received a new grant of 14,517 restricted stock units (RSUs), each tied to either one RXO common share or a cash payment equal to its fair market value upon settlement.
When do the newly granted RXO RSUs vest?
The 14,517 RSUs granted to the director are scheduled to vest in full on January 2, 2027, subject to the director’s continued service on RXO’s board.
What RSUs vested for the RXO director on January 2, 2026?
RSUs previously granted to the director vested on January 2, 2026, resulting in the issuance of 7,745 shares of RXO common stock at a price of $0 per share.
What does each RXO restricted stock unit (RSU) represent in this filing?
Each RSU represents a contingent right to receive, upon settlement, either one share of RXO common stock or a cash payment equal to the fair market value of one share of common stock.